

Vaccine Updates

2/16/22

CDC Updates

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Reference Materials

[Summary Document for Interim Clinical Considerations](#) 

[COVID-19 Vaccine Administration Error Revaccination Guidance](#) 

[COVID-19 Vaccine Administration Error Revaccination Guidance – Poster](#) 

Get Email Updates

To receive email updates about this page, enter your email address:

[What's this?](#)

Submit

Summary of recent changes (last updated February 11, 2022):

Updated Clinical Considerations for Use of COVID-19 Vaccines

Summary of recent changes (last updated February 11, 2022):

- Updated guidance for moderately or severely immunocompromised people
 - Clarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster dose for a total of 4 doses
 - New guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster dose to at least 3 months (instead of 5 months)
 - New guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose and a booster dose, for a total of 3 doses to be up to date
- Updated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal antibodies or convalescent plasma
- Updated guidance on receiving a booster dose if vaccinated outside the United States
- Updated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA COVID-19 vaccine as a precaution
- Reorganized and condensed multiple sections

COVID-19 Vaccine Products

TABLE 1. COVID-19 vaccine formulations currently approved or authorized in the United States

Vaccine manufacturer	Age indication	Vaccine vial cap color	Dilution required	Primary Series		Booster dose	
				Dose	Injection volume	Dose	Injection volume
Pfizer-BioNTech	5-11 years	Orange	Yes	10 µg	0.2 mL	NA	NA
Pfizer-BioNTech	≥12 years	Purple	Yes	30 µg	0.3 mL	30 µg	0.3 mL
Pfizer-BioNTech	≥12 years	Gray	No	30 µg	0.3 mL	30 µg	0.3 mL
Moderna	≥18 years	NA	No	100 µg	0.5 mL	50 µg	0.25 mL
Janssen	≥18 years	NA	No	5×10 ¹⁰ viral particles	0.5 mL	5×10 ¹⁰ viral particles	0.5 mL

Recommendations for General Population

TABLE 2. COVID-19 vaccination schedule for the primary series in the general population*

Primary series vaccine manufacturer	Age group	Number of doses in primary series	Number of booster doses	Interval between 1st and 2nd dose	Interval between primary series and booster dose
Pfizer-BioNTech	5–11 years	2	NA	3 weeks	NA
Pfizer-BioNTech	≥12 years	2	1	3 weeks	≥5 months
Moderna	≥18 years	2	1	4 weeks	≥5 months
Janssen	≥18 years	1	1	NA	≥2 months

Revised Recommendations for Immunocompromised Persons

Table 3: COVID-19 vaccination schedule for people with moderate or severe immunocompromise*

Primary vaccination	Age group	Number of primary vaccine doses	Number of booster doses	Interval between 1st and 2nd dose	Interval between 2nd and 3rd dose	Interval between 3rd and 4th dose
Pfizer-BioNTech	5–11 years	3	NA	3 weeks	≥4 weeks	N/A
Pfizer-BioNTech	≥12 years	3	1	3 weeks	≥4 weeks	≥3 months
Moderna	≥18 years	3	1	4 weeks	≥4 weeks	≥3 months
Janssen	≥18 years	1 Janssen, followed by 1 mRNA	1	4 weeks	≥2 months	N/A

See [Appendix B](#) for additional dose information for Janssen COVID-19 Vaccine recipients.


COVID-19 Booster Safety

- 82.6 million U.S. residents 18+ received a booster as of 2/6/22
- V-safe analysis:
 - 721,562 booster recipients
 - Local and systemic reactions were *less frequent* following booster dose compared to dose 2
- VAERS analysis:
 - 39,286 reports of adverse events following booster dose
 - 92.4% of reports were non-serious
 - 37 reports of myocarditis

Pfizer COVID-19 Vaccine for Young Children Age 6 months to 4 years old

- **FDA VRBPAC meeting initially scheduled for 2/15 postponed**
 - “The U.S. Food and Drug Administration has been notified by Pfizer that new data have recently emerged regarding its emergency use authorization request for the use of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months through 4 years of age ... Based on the agency’s preliminary assessment, and to allow more time to evaluate additional data, we believe additional information regarding the ongoing evaluation of a third dose should be considered as part of our decision-making for potential authorization.”


COVID-19 SKILLED NURSING FACILITIES TRENDS



- (1) May 2-Predictive analytics are initiated.
- (2) June 1-Mitigation plans are due from all SNFs, and baseline COVID-19 testing is initiated.
- (3) June 30-Baseline testing is completed.

CA SNF Resident Cases by Vaccination Status

SNF Resident Cases Per 1,000




Booster* Vaccinations in CA

as of February 14, 2022

Booster Rates by Age Group

■ 12 to 17 ■ 18 to 49 ■ 50 to 64 ■ 65+

56%
of total eligible
population



*Includes Additional Doses

Modeling Estimates CA COVID-19 Vaccination Program Prevented >1.5 million COVID-19 Cases

Table 1: Comparison of primary and alternative model to estimate the number of COVID-19 cases averted due to vaccination in California by age group

	Age group (years)	Observed cases	Predicted COVID-19 cases (95% PI or UI)	Averted COVID-19 cases (95% PI or UI)	Relative reduction in % (95% PI or UI)
Primary model	Total (≥ 12)	2,983,152	4,506,630 (3,959,910, 5,071,680)	1,523,500 (976,800, 2,230,800)	34 (25, 43)
	12-17	238,031	278,960 (268,300, 290,120)	40,930 (30,270, 52,090)	15 (11, 18)
	18-49	1,829,625	2,866,350 (2,444,720, 3,412,980)	1,036,700 (615,100, 1,588,300)	36 (25, 46)
	50-64	588,553	894,900 (810,040, 1,003,720)	306,300 (221,500, 415,200)	34 (27, 41)
	≥ 65	326,943	466,410 (436,850, 507,170)	139,500 (109,900, 180,200)	30 (25, 36)

COVID-19 mRNA Vaccine Effectiveness against ED/UC Encounters during Omicron

TABLE 2. mRNA COVID-19 vaccine effectiveness* against laboratory-confirmed COVID-19–associated† emergency department and urgent care encounters and hospitalizations among adults aged ≥18 years, by number and timing of vaccine doses[§] — VISION Network, 10 states,¶ August 2021–January 2022**

Characteristic	Total	SARS-CoV-2 positive test result no. (%)	VE fully adjusted % (95% CI)*	Waning trend p value††
ED/UC encounters				
Omicron-predominant period				
Unvaccinated (Ref)	24,799	13,991 (56)	—	—
Any mRNA vaccine, 2 doses	19,822	8,351 (42)	41 (38–43)	<0.001
<2 mos	555	157 (28)	69 (62–75)	
2–3 mos	1,982	785 (40)	50 (45–55)	
4 mos	1,234	509 (41)	48 (41–54)	
≥5 mos	16,051	6,900 (43)	37 (34–40)	
Any mRNA vaccine, 3 doses	10,931	1,938 (18)	83 (82–84)	<0.001
<2 mos	4,993	710 (14)	87 (85–88)	
2–3 mos	5,217	986 (19)	81 (79–82)	
4 mos	692	224 (32)	66 (59–71)	
≥5 mos	29	18 (62)	31 (–50–68)	

Booster protection against Omicron ED/UC encounters wanes over time

COVID-19 mRNA Vaccine Effectiveness against Hospitalization during Omicron

TABLE 2. mRNA COVID-19 vaccine effectiveness* against laboratory-confirmed COVID-19-associated† emergency department and urgent care encounters and hospitalizations among adults aged ≥18 years, by number and timing of vaccine doses§ — VISION Network, 10 states,¶ August 2021–January 2022**

Characteristic	Total	SARS-CoV-2 positive test result no. (%)	VE fully adjusted % (95% CI)*	Waning trend p value††
Omicron-predominant period				
Unvaccinated (Ref)	3,911	1,890 (48)	—	—
Any mRNA vaccine, 2 doses	3,619	979 (27)	55 (50–60)	0.01
<2 mos	88	22 (25)	71 (51–83)	
2–3 mos	294	69 (23)	65 (53–74)	
4 mos	150	42 (28)	58 (38–71)	
≥5 mos	3,087	846 (27)	54 (48–59)	
Any mRNA vaccine, 3 doses	2,833	276 (10)	88 (86–90)	<0.001
<2 mos	1,261	103 (8)	91 (88–93)	
2–3 mos	1,383	137 (10)	88 (85–90)	
≥4 mos	189	36 (19)	78 (67–85)	

Booster protection against Omicron hospitalization wanes over time, but remains >70%

CA Resources for Providers

- California COVID-19 Vaccination Program

<https://eziz.org/covid/>

- Program Updates
- Provider Enrollment
- Vaccine Administration
 - Training for Vaccinators
 - Clinical considerations and Recommendations
 - **Long-Term Care Facility Resources**

<https://eziz.org/covid/vaccine-administration/#l>

- Patient Resources

Long-Term Care Facility Resources

- [Long-Term Care Facility COVID-19 Vaccine Toolkit](#) (CDPH)
- [Importance of COVID-19 Vaccination for Residents](#) (CDC)
- [Pharmacy Partnership for Long-Term Care FAQs](#) (CDC)
- [Post Vaccine Considerations for Residents](#) (CDC)
- [Interim Considerations for COVID-19 Vaccination of Healthcare Personnel and Long-Term Care Facility Residents](#) (CDC)
- [Everyone in Long-Term Care Needs Protection Against COVID-19 and Influenza poster | Spanish | Tagalog](#) (CDPH)

CDC and HHS Resources

- [CDC Interim Clinical Considerations for Use of COVID-19 Vaccines](#)
- [CDC COVID-19 Vaccines for Long-term Care Residents](#)

Frequently Asked Questions (FAQs)

- [Frequently Asked Questions about COVID-19 Vaccination in Long-Term Care Facilities \(CDC\)](#)
- [Frequently Asked Questions about COVID-19 Vaccination \(CDC\)](#)
- [Myths and Facts about the COVID-19 Vaccine \(CDC\)](#)
- [FAQs about COVID-19 Boosters \(HHS\)](#)
- [Community Toolkit for Addressing Health Misinformation \(HHS\)](#)